RAPT Therapeutics (RAPT) director receives 4,956 RSUs in annual equity grant

Rhea-AI Filing Summary

RAPT Therapeutics director Ashley L. Dombkowski received an annual equity grant in the form of restricted stock units. On 01/30/2026, she was awarded 4,956 RSUs of RAPT common stock at a grant price of $0. These RSUs were issued under RAPT’s Amended & Restated Non-Employee Director Compensation Policy.

The 4,956 RSUs fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of RAPT common stock upon vesting, and all 4,956 shares are reported as directly owned following this grant.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dombkowski Ashley L.

(Last) (First) (Middle)

C/O RAPT THERAPEUTICS, INC.

561 ECCLES AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RAPT Therapeutics, Inc. [ RAPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	01/30/2026		A		4,956	A	$0	4,956	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the annual grant of restricted stock units ("RSUs") under the Issuer's Amended & Restated Non-Employee Director Compensation Policy, as currently in effect, which fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock upon vesting.

	/s/ Rodney Young, Attorney-in-Fact	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did RAPT (RAPT) report for Ashley L. Dombkowski?

RAPT reported an annual equity grant to director Ashley L. Dombkowski. On January 30, 2026, she received 4,956 restricted stock units of common stock at a grant price of $0 under the non-employee director compensation policy.

How many RAPT Therapeutics RSUs did Ashley L. Dombkowski receive?

Ashley L. Dombkowski received 4,956 restricted stock units of RAPT common stock. The filing shows these 4,956 shares as directly owned following the transaction, reflecting the full amount of this annual non-employee director equity grant.

When do Ashley L. Dombkowski’s RAPT RSUs vest?

The 4,956 restricted stock units granted to Ashley L. Dombkowski fully vest on the first anniversary of the January 30, 2026 grant date. Vesting must occur before each RSU delivers one share of RAPT common stock to the director.

What does each RAPT RSU granted to Ashley L. Dombkowski represent?

Each restricted stock unit granted to Ashley L. Dombkowski represents a contingent right to receive one share of RAPT common stock upon vesting. This means shares are only delivered after vesting conditions under the director compensation policy are satisfied.

Under what policy were Ashley L. Dombkowski’s RAPT RSUs granted?

The RSUs were granted under RAPT’s Amended & Restated Non-Employee Director Compensation Policy. This policy governs annual equity awards to non-employee directors, including vesting terms such as full vesting one year after the January 30, 2026 grant date.